Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (361-370 of 388) with videos related to

Pageof 39
Sort By:
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
The New England Journal of Medicine|March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaRobert J Motzer, Nizar M Tannir, David F McDermott, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
Pageof 39

Showing results (361-370 of 388) with videos related to

Sort By:
Pageof 39
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Targeted Oncology|September 17, 2024
Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)Daniele Santini, Haoran Li, Giandomenico Roviello, et al.
Cancer Immunology, Immunotherapy : CII|November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 studyRay Manneh Kopp, Francesco Massari, Enrique Grande, et al.
The New England Journal of Medicine|March 22, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaRobert J Motzer, Nizar M Tannir, David F McDermott, et al.
Scientific Reports|August 26, 2024
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world studyMimma Rizzo, Andrey Soares, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII|May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
The New England Journal of Medicine|August 21, 2024
Belzutifan versus Everolimus for Advanced Renal-Cell CarcinomaToni K Choueiri, Thomas Powles, Katriina Peltola, et al.
European Journal of Cancer (Oxford, England : 1990)|August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trialOrazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III StudyRobert J Motzer, Camillo Porta, Masatoshi Eto, et al.
Pageof 39